Page 2009 - Hematology_ Basic Principles and Practice ( PDFDrive )

Chapter 117 Transfusion Therapy for Coagulation Factor Deficiencies 1780.e3

98. Nilsson IM, Hedner U: Immunosuppressive treatment in haemo- 117. Ness PM, Budzynski AZ, Olexa SA, et al: Congenital hypofibrinogen-
philiacs with inhibitors to factor VIII and factor IX. Scand J Haematol emia and recurrent placental abruption. Obstet Gynecol 61(4):519–523,
16(5):369–382, 1976. 1983.
99. Nilsson IM, Jonsson S, Sundqvist SB, et al: A procedure for removing 118. Inamoto Y, Terao T: First report of case of congenital afibrinogenemia
high titer antibodies by extracorporeal protein-A-sepharose adsorption with successful delivery. Am J Obstet Gynecol 153(7):803–804, 1985.
in hemophilia: substitution therapy and surgery in a patient with 119. Franchini M, Lippi G: Fibrinogen replacement therapy: a critical review
hemophilia B and antibodies. Blood 58(1):38–44, 1981. of the literature. Blood Transfus 10(1):23–27, 2012.
100. Nilsson IM, Berntorp E, Zettervall O: Induction of immune tolerance 120. Lancellotti S, Basso M, De Cristofaro R: Congenital prothrombin
in patients with hemophilia and antibodies to factor VIII by combined deficiency: an update. Semin Thromb Hemost 39(6):596–606, 2013.
treatment with intravenous IgG, cyclophosphamide, and factor VIII. N 121. Breederveld J, Giddings JW, Ten Cate JW, et al: The localization of
Engl J Med 318(15):947–950, 1988. factor V within normal human platelets and the demonstration of a
101. Nilsson IM: The management of hemophilia patients with inhibitors. platelet-factor V antigen in congenital factor V deficiency. Br J Hematol
Transfus Med Rev 6(4):285–293, 1992. 29:405–412, 1975.
102. Rituximab to Treat Severe Hemophilia A (RICH). <http:// 122. Mariani G, Testa MG, Di Paolantonio T, et al: Use of recombinant,
clinicaltrials.gov/ct2/show/NCT00331006?term=rituximab+AND+he activated factor VII in the treatment of congenital factor VII deficien-
mophilia&rank=1>. cies. Vox Sang 77(3):131–136, 1999.
103. Leissinger C, Josephson CD, Granger S, et al: Rituximab for treatment 123. White B, O’Connor H, Smith OP: Successful use of recombinant VIIa
of inhibitors in haemophilia A. A Phase II study. Thromb Haemost (Novoseven) and endometrial ablation in a patient with intractable
112(3):445–458, 2014. menorrhagia secondary to FVII deficiency. Blood Coagul Fibrinolysis
104. Carcao M, St Louis J, Poon MC, et al: Rituximab for congenital 11(2):155–157, 2000.
haemophiliacs with inhibitors: a Canadian experience. Haemophilia 124. Hunault M, Bauer KA: Recombinant factor VIIa for the treatment of
12(1):7–18, 2006. congenital factor VII deficiency. Semin Thromb Hemost 26(4):401–405,
105. Collins PW, Mathias M, Hanley J, et al: Rituximab and immune toler- 2000.
ance in severe hemophilia A: a consecutive national cohort. J Thromb 125. Roberts HR: Clinical experience with activated factor VII: focus on
Haemost 7(5):787–794, 2009. safety aspects. Blood Coagul Fibrinolysis 9(Suppl 1):S115–S118, 1998.
106. Franchini M, Mannucci PM: Inhibitor eradication with rituximab in 126. Mumford AD, Ackroyd S, Alikhan R, et al: Guideline for the diagnosis
haemophilia: where do we stand? Br J Haematol 165(5):600–608, 2014. and management of the rare coagulation disorders: a United Kingdom
107. Rodeghiero F, Castaman G, Dini E: Epidemiological investigation of Haemophilia Centre Doctors’ Organization guideline on behalf of
the prevalence of von Willebrand’s disease. Blood 69(2):454–459, 1987. the British Committee for Standards in Haematology. Br J Haematol
108. Nilsson IM, Blomback M, Jorpes E, et al: Von Willebrand’s disease 167(3):304–326, 2014.
and its correction with human plasma fraction 1-0. Acta Med Scand 127. A Study Investigating Treatment Factor X in People With Factor X Defi-
159(3):179–188, 1957. ciency. <http://clinicaltrials.gov/ct2/show/NCT00930176?term=phase
109. Slaby JDT, Fisher P, et al: Von Willebrand factor (vWF) concentrates: +III+AND+high+purity+factor+X+AND+moderate&rank=1>.
correlation of vWF multimer patterns, factor VIII and ristocetin cofac- 128. Seligsohn U: Factor XI deficiency. Thromb Haemost 70(1):68–71, 1993.
tor activities and therapeutic efficacy [abstract]. Haemophilia 2000. 129. Aledort LM: Treatment of factor XI deficiency. Clin Adv Hematol Oncol
110. Mannucci PM, Tenconi PM, Castaman G, et al: Comparison of four 9(4):305–306, 2011.
virus-inactivated plasma concentrates for treatment of severe von Will- 130. Castaman G, Ruggeri M, Rodeghiero F: Clinical usefulness of desmo-
ebrand disease: a cross-over randomized trial. Blood 79(12):3130–3137, pressin for prevention of surgical bleeding in patients with symptomatic
1992. heterozygous factor XI deficiency. Br J Haematol 94(1):168–170, 1996.
111. Agrawal YP, Dzik W: The vWF content of factor VIII concentrates. 131. Corifact Prescribing Information. <http://www.corifact.com/>.
Transfusion 41(1):153–154, 2001. 132. Brand-Staufer B, Carcao M, Kerlin BA, et al: Pharmacokinetic char-
112. Burnouf-Radosevich M, Burnouf T: Chromatographic preparation of acterization of recombinant factor XIII (FXIII)-A2 across age groups
a therapeutic highly purified von Willebrand factor concentrate from in patients with FXIII A-subunit congenital deficiency. Haemophilia
human cryoprecipitate. Vox Sang 62(1):1–11, 1992. 21(3):380–385, 2015.
113. Goudemand J, Mazurier C, Marey A, et al: Clinical and biological 133. Haussmann U, Fischer J, Eber S, et al: Hepatic veno-occlusive disease in
evaluation in von Willebrand’s disease of a von Willebrand factor pediatric stem cell transplantation: impact of pre-emptive antithrombin
concentrate with low factor VIII activity. Br J Haematol 80(2):214–221, III replacement and combined antithrombin III/defibrotide therapy.
1992. Haematologica 91(6):795–800, 2006.
114. Baxter Meets Primary Efficacy Endpoint in Phase 3 Trial of BAX 111, 134. Bernard GR, Vincent JL, Laterre PF, et al: Efficacy and safety of
Investigational Stand-Alone Recombinant Treatment for Von Willebrand recombinant human activated protein C for severe sepsis. N Engl J
Disease. <www.baxter.com>: Baxter; 2014. Med 344(10):699–709, 2001.
115. Feinstein D: Inhibitors of blood coagulation, New York, 2000, Churchill 135. Marti-Carvajal AJ, Sola I, Lathyris D, et al: Human recombinant
Livingstone. activated protein C for severe sepsis. Cochrane Database Syst Rev
116. Goodwin TM: Congenital hypofibrinogenemia in pregnancy. Obstet (4):CD004388, 2011.
Gynecol Surv 44(3):157–161, 1989.